Enter your terms above and click the 'Search' button.

Showing articles 0 to 6 of 6 Filter Applied: multiple sclerosis,treatment of (Click to remove) Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy Neurol 91:e359-e363, Rauer,S.,et al, 2018 Alemtuzumab for Multiples Sclerosis: Who and When to treat? Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012 Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011 Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009 Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008 Cladribine in Treatment of Chronic Progressive Multiple Sclerosis Lancet 344:3-13, Sipe,J.C.,et al, 1994 Showing articles 0 to 6 of 6